COVID-19 has been a catalyst for technologies that are key infrastructure for decentralized clinical trials (DCTs). The pandemic has sped adoption of remote data collection, telehealth, and mobile research technology — from sensors and wearables to complex home monitoring systems.
But just because technology-enabled DCTs are available, it doesn’t mean a full-throttle approach is appropriate in every setting, or that such DCTs should look the same in each case. In this PharmaVOICE article, we discuss best practices for creating fit-for-purpose DCT solutions that meet multiple stakeholder needs, with flexibility and agility, to steer clear of one-size-fits all approaches.
Read the article on the PharmaVOICE website.